Neurocrine Reports Positive Data for INGREZZA in TD Patients

Neurocrine Biosciences Inc. (NBIX) announces promising results from the Phase 4 KINECT-PRO study, highlighting the drug INGREZZA's effectiveness in treating tardive dyskinesia's diverse impacts on patients. Positive outcomes could influence stock price favorably.

Date: 28-02-2025

AI Rating: 7

Positive Outcomes in Clinical Study
Neurocrine Biosciences, through its Phase 4 study KINECT-PRO, reported significant and sustained effects of its product INGREZZA on patients suffering from tardive dyskinesia (TD). The study demonstrated improvements in physical, social, and emotional aspects of life, indicating a robust performance of INGREZZA in addressing this condition.

The KINECT-PRO study utilized validated patient-reported outcome scales, providing comprehensive insights into the patient's experience. This approach emphasizes the drug's capacity to improve quality of life for individuals with TD, highlighting a strong market efficacy.

In the study's findings, not only were there considerable improvements noted from the baseline after treatment, but improvements were also observed early on, as early as four weeks into treatment for patients on the lowest dosage of 40 mg. This rapid onset of effect could be very appealing to healthcare providers and investors alike.

Moreover, the study showcased sustained reductions in involuntary movements as measured by the Abnormal Involuntary Movement Scale (AIMS), consistent across varying severities of TD and not influenced by the patients’ underlying psychiatric conditions. The safety profile of INGREZZA remained stable, with no new risks identified, assuring confidence in its continued use and market presence.

Stocks: NBIX